

S. 932, Give Kids a Chance Act of 2025

Section 1. Short Title.

Establishes the short title as the “Give Kids a Chance Act of 2025.”

Section 2. Research into Pediatric Uses of Drugs; Additional Authorities of Food and Drug Administration regarding Molecularly Targeted Cancer Drugs.

This section provides the Food and Drug Administration (FDA) the authority to require pediatric cancer trials for new drugs that are used in combination with active ingredients that meet the standard of care for targeting pediatric cancer or have been approved to treat adult cancer and are directed at molecular targets for pediatric cancer.

Section 3. Extension of Authority to Issue Priority Review Vouchers to Encourage Treatments for Rare Pediatric Diseases.

This section extends the FDA priority review voucher program through FY2029, to incentivize the development of drugs for rare pediatric diseases. It also requires a study from the Government Accountability Office on the effectiveness of the pediatric PRV program.